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Introduction
ROP occurs because the retina of a preterm infant at birth is incompletely vascularized and
if the postnatal environment does not match the in utero environment that supported retinal
development, the vessels and neural retina will not grow normally. Risk factors determined
from many clinical studies and animal studies fall into two categories1:
1. Prenatal factors
Those that reflect the degree of incomplete neurovascular development at birth
indicating the susceptibility of the retina to harm
a. Gestational age at birth
b. Birth weight
2. Postnatal factors
Factors after preterm birth that differ from the in utero environment of the third
trimester and therefore do not match the extra-uterine needs of the baby and
prevent resumption of normal retinal neurovascular growth after birth:
a. exposure to oxygen which is higher and/or more variable than that found
during gestation that alters the oxygen-regulated growth factors
b. loss of the maternal-fetal interaction resulting in:
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Increased metabolic demands2 in the face of loss of nutrition
(including essential fatty acids)
Decreased IGF-I levels and loss of other factors resulting in poor
postnatal growth and weight gain3–5
Much of our understanding of retinopathy of prematurity (ROP) has come from observations
in the clinic, followed by animal studies to determine pathogenesis, which then are played
out in clinical intervention studies resulting in changes in clinical practice. Optimally this
cycle continues to refine patient care.
ROP was first described as “retrolental fibroplasia” by Terry in 1942.6 In 1952, Patz and
coworkers demonstrated in a clinical study the association between oxygen and ROP7. In an
experimental kitten model8, Ashton then established the concepts of oxygen toxicity and
vessel loss (phase I) followed by hypoxia-mediated vasoproliferation (phase II). Thus these
studies characterized ROP as a two-phased disease of preterm infants with initial cessation
of vessel growth caused by exposure to high levels of oxygen and loss of formed vessels
followed by pathological neovascularization of the retina. As a result of these findings,
oxygen use was severely curtailed for a time and although ROP incidence decreased, many
infants died as a result.9
The balance between sufficient supplemental oxygen to prevent death versus minimal
oxygen to prevent ROP has still not been settled for premature infants at different
gestational and postmenstrual ages despite a large number of clinical studies addressing
aspects of the question.10 The effect of supplemental oxygen use in phase I and phase II of
ROP in these studies suggests that high oxygen saturation levels in phase I is a significant
risk factor and oxygen supplementation in phase II may reduce ROP risk slightly but may
also increase lung disease.11, 12 These studies though hinting at the best use are not yet
definitive and we await a clinical study that will better inform optimal use of oxygen at
different GA, different PMA.
ROP persists as a major cause of blindness in children despite better oxygen monitoring13, 14
as neonatal practices improve and infants at earlier gestational ages survive, with extreme
retinal immaturity at birth.15 The immature retina is susceptible not only to oxygen levels
higher than those in utero but also to variable oxygen tensions and to lack of growth factors
and nutrients normally provided in utero, all of which cause vessel loss and cessation of
vessel growth.
Studies using animal models of oxygen-induced retinopathy (OIR) have rationalized current
ROP treatment and also identified new therapeutic interventions, which may be used to
prevent or predict ROP.
Pathogenesis of ROP
What contributes to the susceptibility of the immature retina of the preterm infant and what
are the differences between the in utero and extra uterine environment that contribute to the
cessation of postnatal retinal vascular growth?
Normal retinal development
To understand pathology, we must understand normal retinal vascular development. In the
human, retinal vascularization occurs predominantly in the second and third trimesters in
utero and reaches maturity at 36 to 40 weeks postmenstrual age (PMA) through
vasculogenesis and angiogenesis.8, 16, 17 The scaffold of the future retinal vasculature is laid
Smith et al. Page 2
Clin Perinatol. Author manuscript; available in PMC 2014 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
down by vascular precursor cells (vasculogenesis) from 12 weeks to ~21 weeks gestational
age, before viable preterm birth.18, 19
Angiogenesis commences at approximately 17 weeks PMA and expands on the vascular
scaffold starting at the optic nerve radiating outward. New vessels bud from existing ones
until vascular development is complete, just prior to full term birth.19 Angiogenesis is
stimulated by the “physiologic hypoxia” of the developing retina described in animal
studies20. That is, when the metabolic demands of the maturing neural retina outpace the
oxygen supplied by the underlying choroid, and the encroaching retinal vascular network,
vasoactive factors (particularly VEGF) are secreted by the avascular retina, which stimulates
new vessel formation.8, 20–22
Phase I ROP: interruption of development with hyperoxia and under-
nutrition
Just as the formation of the retinal vasculature responds to “physiological” hypoxia with
developmental progression, it is sensitive to non-physiological hyperoxia, which is often
encountered after preterm birth. The oxygen saturation of the fetus in the uterine
environment is ~60–70%. Thus preterm birth into room air often causes an increase in
oxygen saturation, which is further exacerbated by supplemental oxygen.23 Hyperoxia
suppresses “physiologic hypoxia” causing down-regulation of hypoxia-inducible factor (Hif)
regulated growth factors resulting in disruption of normal vascular development8, 24.
Notably, the loss of factors from the maternal fetal interface, (e.g. nutrition and other
mediators of postnatal growth) also contributes to low serum IGF-I and disruption in vessel
growth and phase I of ROP.24
Phase II ROP
In severely affected infants, a proliferative phase (Phase II), follows the vessel loss of Phase
I.8 The degree of hypoxia and extent of avascular retina induced by phase I ROP determines
the degree of hypoxia-derived proliferative factors, which determine the degree of phase II
ROP. Phase II begins to develop after more than 32 postmenstrual weeks but can have a
wide range of onset.25, 26 Even infants born at 32 weeks GA are susceptible to vessel loss
when exposed to very high oxygen saturations after birth resulting in severe proliferative
ROP.27
The transition to phase II occurs when the attenuated vasculature cannot supply enough
oxygen (and nutrients) to the developing retina, leading to increased expression of hypoxia-
induced factors. These growth factors then stimulate aberrant vessel formation at the
junction between vascularized and avascular retina.24 Paradoxically these pathological
vessels do not reperfuse the avascular retina but stop at the avascular junction. If the retina
receives ample oxygenation, then these pathologic vessels may regress. If the demands of
the retina continue to outstrip the oxygen and nutrient supply, then exuberant
neovascularization may continue.8 Neovascular proliferation may cause retinal folds,
macular dragging, and cicatricial changes sometimes ultimately causing retinal detachment
and blindness. (Figure 1)
Molecular mechanism of oxygen influences on phase I and II of ROP
Animal Models of Oxygen-induced Retinopathy
Following the first description of the disease in the earliest studies7, 28 animal studies have
uncovered the molecular mediators of the effects of hyperoxia and hypoxia on retinal
vascular development.2329, 30 Animal models of oxygen-induced retinopathy (OIR) have
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been developed in the neonatal kitten, dog, rat, and mouse. The mouse OIR model is
currently the most commonly used model as it is reproducible, can be reliably quantified and
can be manipulated genetically.3024 (Figure 2)
Hypoxia induced factors and ROP: Vascular endothelial growth factor
(VEGF)
The role of the endothelial cell mitogen and vascular permeability factor VEGF which plays
a critical role in both phase I and phase II ROP was first described in animal studies of
OIR.21, 22, 30–37
Phase I: VEGF is suppressed by hyperoxia, suppressing normal vessel
growth
During retinal development, the wave front of “physiologic hypoxia” resulting from
increasing metabolic demand of developing neurons, induces a wave of VEGF, which
results in extension of forming vessels The VEGF wave is suppressed with exposure to
hyperoxia, causing cessation of normal vascular development seen in phase I of
ROP.20, 29–32, 36
In mouse OIR, after 6 hours exposure to 75% oxygen, both VEGF mRNA and protein levels
are suppressed with loss of microvessels and cessation of new vessel formation.22 This
vessel loss can be inhibited by intravitreal injection of VEGF or the VEGFR-1 specific
ligand placental growth factor-1 (PlGF-1).22, 33
Clinical Implications of VEGF and Phase I of ROP
This demonstrates that oxygen suppression of VEGF during phase I of ROP is a major
contributor to vessel loss. These animal studies rationalize the judicious use of oxygen
during the early postnatal period where there is incomplete retinal vascularization to
minimize VEGF suppression to minimize vessel loss.
Phase II
VEGF is over-expressed in phase II causing neovascularization
In the mouse OIR model, with return to room air, the now vaso-compromised retina
becomes hypoxic which induces VEGF mRNA and protein expression21, which are directly
linked to aberrant neovascularization.21, 22, 34, 35
Clinical implications of VEGF in phase II of retinopathy
Studies in the OIR model again help us understand the pathogenesis of phase II, showing
that neovascularization can be inhibited by targeting VEGF in phase II with intravitreal
injections of anti-VEGF compounds including antisense oligodeoxynucleotides, antibodies
against VEGF or small interfering RNA (siRNA).34, 35, 38 These animal studies are the basis
of the clinical use of intravitreal injections of anti-VEGF drugs for retinopathy and for age
related macular degeneration (AMD).
Several VEGF inhibitors have been FDA approved for intraocular injection to treat
neovascular AMD and diabetic macular edema including an antibody fragment Lucentis©
(ranibizumab). The full anti-VEGF antibody, Avastin© (bevacizumab), is used off label for
treatment of these diseases. Although Avastin is neither approved for use in eyes, nor in
infants, and intravitreal Avastin injections suppress serum VEGF for weeks in preterm
infants39, reports of its use is steadily increasing. There are several case reports of the use of
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these agents with moderate success in severe cases of ROP which have been refractory to
laser treatment40 or in patients with vitreal bleeding or opaque media unsuitable for laser
treatment.41 In these reports, there was regression of ROP with no adverse systemic or
intraocular outcomes reported.
Mintz-Hittner and Kuffel studied the effects of bevacizumab treatment of moderate and
severe ROP in eyes that had not previously undergone laser ablation.42 Twenty-two eyes
received intravitreal injection of bevacizumab. The mean follow up was 48.5 weeks. After a
single injection, treatment was considered successful in all eyes. Adverse systemic or
intraocular outcomes were not examined.42
New anti-VEGF studies needed to optimize clinical care
Just as the optimal balance point must be found with supplemental oxygen- enough to
prevent brain dysfunction and death but not so much that vascular growth in the eye is
suppressed, the balance between sufficient and insufficient VEGF is unknown. In phase I
ROP, hyperoxia downregulates VEGF thereby pruning the vascular tree since fewer vessels
are needed with high oxygen. However in the hypoxic phase II there is again a need for
more vessels and VEGF is dramatically up-regulated, contributing to aberrant vessel
growth.43
A large randomized controlled clinical trial is needed to determine the appropriate anti-
VEGF agent, the appropriate dosing and timing of treatment as well as the long-term ocular
and systemic outcomes. While current limited studies appear promising, careful attention
must be paid to assess potential long term ophthalmic and neurological and other systemic
consequences of VEGF inhibitor use in the developing neonate since rapid VEGF-dependent
development of vital organs such as brain, lungs and kidneys normally takes place during
the third trimester. Anti-VEGF treatment could compromise this development.
VEGF and Laser Ablation Treatment of ROP
Over the last few decades, treatment with retinal ablation (cryotherapy and laser therapy)
during phase II of ROP, have decreased severe vision loss.44–46 The mechanism of the
ablative treatment has been rationalized in terms of animal studies showing that hypoxic
retina (that is destroyed by these interventions) is the source of angiogenic factor release that
causes vasoproliferation. This was confirmed in an autopsy study showing that laser
photocoagulation reduced VEGF expression in ROP treated retina compared to an untreated
fellow eye.47, 48
Erythropoietin (Epo)
Erythropoietin (Epo) is a second hypoxia-induced factor, independent of VEGF, which has
been shown in in vitro and in vivo in studies in the OIR mouse to be important in normal
retinal angiogenesis in phase I and in neovascularization in phase II of oxygen-induced
retinopathy.24 In vitro Epo is as potent as VEGF in inducing angiogenesis.49, 505152, 53 Epo
is secreted locally in the retina as well as by the fetal liver and adult kidney to induce
erythopoiesis in the bone marrow, apoptosis in neurons and vascular cells, and
angiogenesis.37
Clinical implications of Epo contributing to ROP
During phase II ROP, Epo levels rise concomitant with neovascularization. There is at
present no anti-Epo drug to inhibit proliferative retinopathy, although the effect of Epo
inhibition in phase II is as great as that of inhibiting VEGF, and development of an anti-Epo
drug could be beneficial.54, 55
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In some NICUs, anemia in premature infants is treated with the administration of
recombinant human Epo (rhEPO).24, 56 In a recent retrospective study of premature babies,
rhEPO treatment was found to be a risk factor for the development of threshold ROP
requiring photoablative laser.56 A Cochrane review suggested that in humans, EPO use was
associated with an increased risk of ROP (any grade) with a similar trend for ROP stage ≥3
although infants were not classified according to PMA.57
Factors lacking after preterm birth and ROP
Insulin-like growth factor-1 (IGF-I)
Animal studies have been instrumental in understanding the influence of postnatal factors
affecting vascular growth on the development of ROP.58 Specifically IGF-I has been shown
to be critical in both phase I and phase II of retinopathy in the OIR model in the mouse.59, 60
IGF-I is a polypeptide that promotes human fetal growth throughout gestation but
particularly in the third trimester, IGF-I levels increase both in the maternal serum and in the
fetus.61 Serum IGF-I levels correlate with weight gain throughout childhood.62
In premature infants, the sudden loss of the maternal fetal interaction (e.g. loss of nutrients
in the setting of increased metabolic demand, loss of placental IGF-1, and other regulating
factors) contributes to the dramatic reduction in serum IGF-I after preterm birth. IGF-I
synthesis in the liver of the fetus/preterm infant is dependent on nutrient supply and level of
maturity.63
Low serum IGF-I has been correlated with decreased fetal growth and development.24, 64
Comparison of the longitudinal serum levels of IGF-I between full term and preterm babies,
show that both groups have a decrease in circulating IGF-I levels after birth. However, full
term infants experience a postnatal surge of IGF-I between day 1 and day 15 of life not seen
in preterm infants.65 The immaturity of the very preterm infant in combination with poorly
known nutritional needs precludes proper accretion of nutrients, which will likely reduce
IGF-I secretion to slow maturation.
Studies in animal models have shown the importance of low IGF-I to the development of
ROP.24, 59, 60 Both growth hormone and its mediator for growth, IGF-I, are important in
angiogenesis. Genetic defects in the growth hormone/IGF-I axis result in subnormal
vascularization of the retina.66 In IGF-I knockout mice, retinal vessel growth is suppressed
although VEGF levels are comparable in wild type and IGF-I−/− mice suggesting that
VEGF is necessary but not sufficient to promote angiogenesis.60
IGF-I is necessary for maximum VEGF signaling of the Akt and MAP kinase pathway
critical for endothelial cell survival and proliferation. This suggests that a minimal level of
IGF-I is required for vascular growth, rationalizing the poor vascular growth seen in phase I
in premature infants with ROP. This is supported by the increased growth and decreased
ROP after early IGF-I treatment reported in starving mouse pups subjected to OIR.67
IGF-I is also important in phase II ROP. There is suppressed neovascularization in the OIR
growth hormone receptor (and IGF-I) deficient mouse, which is restored through exogenous
administration of IGF-I or an IGF-I receptor antagonist. Again, reduction in IGF-I results in
a down-regulation of VEGF-mediated MAPK and Akt pathway activation rather than
directly affecting VEGF levels.59, 68, 69
These animal studies have uncovered the links between IGF-I and VEGF where IGF-I
behaves as a permissive agent in VEGF-mediated angiogenesis. In the premature infant,
vessel growth is suppressed with the drop in circulating IGF-I levels. As the infant grows,
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the body slowly produces endogenous IGF-I; once a threshold is reached, VEGF-induced
neovascularization may ensue.
Clinical Implications: Postnatal IGF-1 levels and postnatal growth predict ROP
These animal studies have also suggested the importance of using either low serum IGF-I or
the linked parameter of poor postnatal weight gain as a predictor for those infants at highest
risk for ROP.3–5, 70–74 They also suggest that IGF-I replacement might prevent ROP and
related complications of premature birth by fostering postnatal growth.75
Based on these studies, which gave rise to an understanding of the relationship between
IGF-I, postnatal growth and angiogenesis, a new diagnostic algorithm “Weight IGF-I
Neonatal ROP” (WINROP™) was developed in 2006. WINROP utilizes rate of postnatal
weight gain as a reflection of IGF-1 or uses weight gain and IGF-I levels together as highly
predictive markers for those infants at increased risk for development of proliferative ROP.
The WINROP algorithm predicts which infants will or will not develop ROP by assessing
deviations in the rate of increase in weight and serum IGF-I of infants who later developed
severe ROP from those who developed no or mild ROP using online statistical surveillance
(www.winrop.com). In the initial cohort of 79 preterm infants followed longitudinally with
weekly postnatal weight and serum IGF-I measurements, all patients who developed
proliferative ROP were identified at least 5 weeks prior to treatment for severe ROP.3
After the initial validations using postnatal changes in both IGF-I and weight gain10, this
algorithm has been used since 2009 with postnatal weight gain alone with validation in
>10,000 infants worldwide. The sensitivity (90%-100%) as well as the specificity (38.7%–
81.7%) has varied in different international preterm populations in Sweden, Switzerland,
Canada, the US, Brazil, and Mexico4, 70–74. This is considered to be due to the different
composition and characteristics of the preterm population in different countries. This tool
also helped to determine early which infants are at low risk thus reducing the number of eye
examinations in that population while concentrating observation on those infants at high
risk.4
With the WINROP algorithm, it has become clear that although treatment may not be
warranted until many weeks postnatally, the initial changes in weight gain in the first several
weeks of life significantly affects ROP development.4 Several other algorithms have since
been developed that confirm that postnatal weight gain can be used to predict later
development of ROP76, 77.
Omega-3 Long Chain Polyunsaturated Fatty Acids (LCPUFAs) in OIR in Mice
Through mouse OIR studies, the important role of the exogenously (usually diet) derived
omega-3 LCPUFA docosahexaenoic acid, DHA in preventing ROP has been
elucidated.24, 7879 In the third trimester there is a massive transfer of essential fatty acids
from mother to fetus, which is lost after preterm birth.
The principal retinal omega-3 LCPUFA is DHA and the main retinal omega-6 LCPUFA is
arachidonic acid (AA). Animal studies have shown that the balance of omega-3 to omega-6
LCPUFA in the retina affects vascular and neuronal survival.24, 78 In extremely preterm
infants who are given lipids mainly from intravenous supplementation which does not
contain omega-3 LCPUFAs there is a deficit of this essential fatty acid, which has been
shown to be critical in preventing retinopathy in animal models.
In phase II ROP, there is a large decrease in the extent of vessel loss (and decreased
neovascularization) in pups raised on an isocaloric diet with 2% of total fatty acids from
omega-3 PUFAs in contrast to a diet enriched in omega-6 PUFAs. This suppression of
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proliferative ROP occurs through improved regrowth of vessels after vessel loss as well as
direct suppression of neovascularization in part through suppression of inflammation.78
Supplementation with the downstream metabolites of omega-3 PUFAs, including
neuroprotectin D1, resolvins D1 and E1, and 4HDHA also prevented
neovascularization.78, 79
Clinical Implication of ROP and DHA
The anti-neovascular effects of the omega-3 PUFA DHA supplementation are as strong as
anti-VEGF therapy in the mouse OIR model suggesting supplementing oral or parenteral
intake of DHA is another potential target to control ROP.24
Summary
ROP is a clinically multifactorial process with potentially devastating effects on vision in
premature infants. Prevention includes improved oxygen control with avoidance of
fluctuations and provision of sufficient nutrition as early as possible. New preventative
strategies including IGF-I replacement and DHA supplementation and possible suppression
of the hypoxia related factor, VEGF, have been identified through insights into the
molecular pathogenesis of ROP in animal studies. Any strategy which seeks to modulate the
key elements in retinal angiogenesis, must consider their phase-specific effects. Further, the
WINROP algorithm and others based on our understanding from mouse studies of IGF-I and
the importance of the related postnatal growth in in premature infants at risk for ROP
provides a novel method of identifying early those infants at highest risk for ROP,
potentially targeting therapy and resources more effectively towards these babies.
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Key points
1. Review the molecular pathogenesis of retinopathy of prematurity (ROP).
2. Understand the role of the hypoxia-induced growth factors, particularly vascular
endothelial growth factor (VEGF), in the normal development of the retinal
vasculature.
3. Understand the contribution of factors lacking after preterm birth; nutrition,
insulin-like growth factor 1 (IGF-I) and polyunsaturated fatty acids (PUFAs), in
normal retinal development.
4. Describe clinical applications for the prevention/treatment of ROP, which have
emerged from molecular studies.
5. Appreciate the importance of neonatal weight gain as a predictor for the
development of ROP.
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Figure 1. Treatment of ROP is based on understanding pathogenesis
1. Laser photocoagulation of ROP: Hypoxic retina anterior to neovascularization in phase
II of ROP which produces VEGF and Epo is destroyed to decrease pathological blood vessel
formation (promoting C to D)
2. Anti-VEGF therapy: Direct suppression of neovascularization with suppression of
VEGF (promoting C to D)
3. Increasing IGF-1 to in utero levels after birth: prevents vessel loss (phase I)
(preventing A to B) to prevent phase II (C)
4. Control of oxygen after preterm birth: Prevents hyperoxia induced suppression of Hif
regulated factors VEGF and Erythropoietin that are necessary for normal retinal vascular
development thus preventing vessel loss (preventing A to B)
5. Maintaining adequate intake of the essential fatty acid DHA after preterm birth:
Promotes normal vascularization and directly inhibits neovascularization (promote B to D
and C to D)
6. Monitoring postnatal growth which is based on rate of increase of postnatal IGF-1
levels: Predicts the future development of neovascular ROP (C)
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Figure 2. Mouse model of oxygen-induced retinopathy
Neonatal mice are exposed to 75% oxygen from postnatal day 7 (P7) until P12 causing
vessel loss and cessation of vascular growth to simulate Phase I of ROP. The central retinal
microvessels are obliterated and radial vascular growth ceases. When the mice are returned
to room air with incompletely vascularized retina, retinal neovascularization is seen, similar
to phase II of ROP. Vessel proliferation is maximum at P17 then regresses, which also
occurs in human ROP. These changes can be quantified in retinal flat mounts.
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